关于 Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.
Source: Wikipedia
行业Biotechnology
总部Hayward, CA
成立2004
法律形式C Corporation
状态营业中
专利1 项专利
PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPASE INHIBITOR SODIUM [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL]OX…JP2011021042A · 2011
关键数据
法律信息
| 法定名称 | Anthera Pharmaceuticals Inc |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1316175在 SEC EDGAR 上查看 ↗ |
| 注册地址 | Hayward, CA |
| 状态 | 营业中 |
来源: SEC EDGAR · 更新于 Nov. 14, 2026